Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 Combined With Tislelizumab for High-risk NMIBC
NCT05957757Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Renji Hospital. Started Aug 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05957757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957757.